Skip to content
value.today

Verax Biomedical Inc.

Total raised
$46 M
8 rounds on record
Latest round
$3 M
Sep 2019
First round on record
Apr 2009
Today
Private
No later event on record

Funding rounds

8 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Verax Biomedical Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Sep 2019$3 MNo. 8$2 to $10 million

Verax Biomedical Inc.: Raise no. 8, Sep 2019

Investors in this round

5 investors had bought by the notice of Sep 19, 2019: 5 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $11 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
Not disclosed
Sales commissions
$425,000
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Lousararian · Executive Officer, Director
  • Paul Ragusa · Executive Officer
  • Joe Sanders · Director
  • Marc Goldberg · Director
  • Robert Flanagan · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

  • Four Points Capital Partners LLC (CRD 43149) · broker-dealer Thomas Frederick Zipser (CRD 5248930) · New York, New YorkSold in MA

Signed by James Lousararian, Chief Executive Officer. Source: SEC Form D, newest notice filed Sep 19, 2019. Read the notice at the SEC.

debt, optionsSEC
Oct 2017$11 MNo. 7$10 to $50 million

Verax Biomedical Inc.: Raise no. 7, Oct 2017

Investors in this round

4 investors had bought by the notice of Nov 13, 2017: 4 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$11 M of $24 M offered; $13 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Lousararian · Executive Officer, Director
  • Joe Sanders · Executive Officer, Director
  • Joe Del Guercio · Director
  • Marc E. Goldberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Lousararian, Chief executive officer. Source: SEC Form D, newest notice filed Nov 13, 2017. Read the notice at the SEC.

equity, optionsSEC
Feb 2016$13 MNo. 6$10 to $50 million

Verax Biomedical Inc.: Raise no. 6, Feb 2016

Investors in this round

64 investors had bought by the notice of Jun 27, 2016: 64 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$13 M of $25 M offered; $12 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Lousararian · Executive Officer, Director
  • Joe R. Sanders · Executive Officer, Director
  • Nancy A. Hornbaker · Executive Officer
  • Paul Remo Ragusa · Executive Officer
  • R. Scott Mckenzie · Executive Officer
  • Yli Remo Vallejo · Executive Officer
  • James E. Koziarz · Director
  • Joe Del Guercio · Director
  • Marc E. Goldberg · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Lousararian, Chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Jun 27, 2016. Read the notice at the SEC.

equity, debt, optionsSEC
Jan 2015$4 MNo. 5$2 to $10 million

Verax Biomedical Inc.: Raise no. 5, Jan 2015

Investors in this round

61 investors had bought by the notice of Jan 21, 2015: 61 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$4 M of $4 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Lousararian · Executive Officer, Director
  • Joe R. Sanders · Executive Officer, Director
  • Nancy A. Hornbaker · Executive Officer
  • Paul Remo Ragusa · Executive Officer
  • R. Scott Mckenzie, Sr. · Executive Officer
  • Yli Remo Vallejo · Executive Officer
  • Buzz Benson · Director
  • James Koziarz · Director
  • Joe Del Guercio · Director
  • Marc Goldberg · Director
  • Robert Zieserl · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Lousararian, Chief executive officer. Source: SEC Form D, newest notice filed Jan 21, 2015. Read the notice at the SEC.

equitySEC
Jul 2013$9 MNo. 4$2 to $10 million

Verax Biomedical Inc.: Raise no. 4, Jul 2013

Investors in this round

83 investors had bought by the notice of Oct 15, 2013: 83 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$9 M of $12 M offered; $3 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Gregory Scott Lawrence · Executive Officer
  • James Lousararian · Executive Officer, Director
  • Joe R. Sanders · Executive Officer, Director
  • Nancy A. Hornbaker · Executive Officer
  • Paul Scott Ragusa · Executive Officer
  • R. Scott Mckenzie, Sr. · Executive Officer
  • Buzz Benson · Director
  • James Koziarz · Director
  • Joe Del Guercio · Director
  • Marc Goldberg · Director
  • Robert Zieserl · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Lousararian, Chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 15, 2013. Read the notice at the SEC.

equity, debt, optionsSEC
Jul 2012$3 MNo. 3$2 to $10 million

Verax Biomedical Inc.: Raise no. 3, Jul 2012

Investors in this round

86 investors had bought by the notice of Oct 25, 2012: 86 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$3 M of $5 M offered; $2 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Greg Scott Lawrence · Executive Officer
  • James Lousararian · Executive Officer, Director
  • Joe R. Sanders · Executive Officer, Director
  • Nancy A. Hornbaker · Executive Officer
  • Paul Scott Ragusa · Executive Officer
  • R. Scott Mckenzie · Executive Officer
  • Buzz Benson · Director
  • James Koziarz · Director
  • Joe Del Guercio · Director
  • Marc Goldberg · Director
  • Robert Zieserl · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Lousararian, Chief executive officer. Source: SEC Form D and 1 amendment, newest notice filed Oct 25, 2012. Read the notice at the SEC.

debt, optionsSEC
Mar 2011$1 MNo. 2Under $2 million

Verax Biomedical Inc.: Raise no. 2, Mar 2011

Investors in this round

26 investors had bought by the notice of Mar 22, 2011: 26 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$1 M of $1 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • James Lousararian · Executive Officer, Director
  • Joe R. Sanders · Executive Officer, Director
  • Nancy A. Hornbaker · Executive Officer
  • R. Scott Mckenzie · Executive Officer
  • Buzz Benson · Director
  • James Koziarz · Director
  • Joe Del Guercio · Director
  • Marc Goldberg · Director
  • Robert Zieserl · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Paul Ragusa, Vice president, finance & administration. Source: SEC Form D, newest notice filed Mar 22, 2011. Read the notice at the SEC.

equitySEC
Apr 2009$2 MNo. 1$2 to $10 million

Verax Biomedical Inc.: Raise no. 1, Apr 2009

Investors in this round

12 investors had bought by the notice of Apr 15, 2009: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$2 M of $10 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • James Lousararian · Executive Officer, Director
  • Jeffrey A. Hall · Executive Officer
  • Joe R. Sanders · Executive Officer, Director
  • Nancy A. Hornbaker · Executive Officer
  • R. Scott Mckenzie · Executive Officer
  • Buzz Benson · Director
  • James Koziarz · Director
  • Joe DEL GUERCIO · Director
  • Marc Goldberg · Director
  • Robert Zieserl · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by James Lousararian, President. Source: SEC Form D, newest notice filed Apr 15, 2009. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Verax Biomedical Inc. chose not to state its revenue in its newest notice of a funding round (Sep 2019).

    SEC Form D · Sep 2019

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Sep 2019

That is all the official record says: Verax Biomedical Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Verax Biomedical Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 8 rounds above had up to 86 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Verax Biomedical Inc.
NameRoleNamed in
James LousararianExecutive officerSep 2019
Paul RagusaExecutive officerSep 2019
Joe SandersExecutive officerNov 2017
Joe R. SandersExecutive officerJun 2016
Nancy A. HornbakerExecutive officerJun 2016
Paul Remo RagusaExecutive officerJun 2016
R. Scott MckenzieExecutive officerJun 2016
Yli Remo VallejoExecutive officerJun 2016
R. Scott Mckenzie, Sr.Executive officerJan 2015
Gregory Scott LawrenceExecutive officerOct 2013
Paul Scott RagusaExecutive officerOct 2013
Greg Scott LawrenceExecutive officerOct 2012
Jeffrey A. HallExecutive officerApr 2009
James LousararianDirectorSep 2019
Joe SandersDirectorSep 2019
Marc GoldbergDirectorSep 2019
Robert FlanaganDirectorSep 2019
Joe Del GuercioDirectorNov 2017
Marc E. GoldbergDirectorNov 2017
James E. KoziarzDirectorJun 2016
Joe R. SandersDirectorJun 2016
Buzz BensonDirectorJan 2015
James KoziarzDirectorJan 2015
Robert ZieserlDirectorJan 2015
Joe DEL GUERCIODirectorApr 2009